Company intelligence / Profile preview

Portal Biotech

Guildford, Surrey, United Kingdom

Ownership: Private
Development stage: Other

Overview

Portal Biotech has developed the world's first commercial platform for full-length, single-molecule protein sequencing and characterization, with instruments now available for collaborative protein characterization services and early-access programs. Their benchtop systems enable detailed analysis of intact proteins and modifications, providing real-time, highly quantitative results for research labs and the biopharma industry, promising significant impact on drug discovery and diagnostics[1][4][6].

Industry: Non-Drug Biotech

Partnerships

Collaborative research with academics, pharma, and biotech through Early Access Programme; investment and collaboration with NATO Innovation Fund, Earlybird Venture Capital, SCVC, Pillar VC, 8VC, Amino Collective, Outsized, We Venture Capital, British Business Bank, WS Investment Company

Beyond the preview

Go deeper on Portal Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Portal Biotech.

Explore the full profile